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In this report, we described induction of HIV envelope (env)-specific systemic and mucosal immune responses by oral
vaccination of BALB/c mice with env-encoded plasmid DNA encapsulated in poly(DL-lactide-co-glycolide) (PLG) micropar-
ticles. We demonstrated that intragastric administration of the encapsulated plasmid DNA resulted in transduced expression
of the env glycoprotein in the intestinal epithelium. Mice immunized orally exhibited env-specific type 1 and cytotoxic T
lymphocyte (CTL) responses in spleen and the inductive (Peyer’s patches) and effector (lamina propria) mucosal tissues of
gut. Oral administration of PLG-encapsulated plasmid DNA encoding gp160 also induced env-specific serum antibodies, and
an increased level of IgA directed to gp160 was detected in fecal washes of the immunized mice. In contrast, intramuscular
(i.m.) administration of naked or PLG-encapsulated DNA vaccine induced only systemic cellular and humoral responses to
the env glycoprotein. Using an HIV env-expressing recombinant vaccinia viral intrarectal murine challenge system, we
observed higher resistance to mucosal viral transmission in mice immunized orally than in animals injected i.m. with
PLG-encapsulated plasmid DNA encoding gp160. Results of these studies demonstrate the feasibility of using orally
delivered PLG microparticles containing plasmid DNA-encoded HIV gp160 for induction of env-specific systemic and
mucosal immune responses and protection against recombinant HIV env vaccinia virus challenge. © 2000 Academic Press
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eINTRODUCTION
Development of a safe, effective, and affordable vac-
cine represents the best hope for containing the spread
and consequences of human immunodeficiency virus
(HIV) epidemic worldwide. Because ;80% of HIV-sero-
positive individuals acquired the infection via mucosal
surfaces (Miller et al., 1992; Phillips et al., 1994), this
trongly implies that HIV-specific immunity at mucosal
ites is critical for the control of infection in many indi-
iduals exposed to the virus. This observation has been
upported by studies with the simian immunodeficiency
irus (SIV) in monkeys, which demonstrated a protective
ole of systemic immunizations against parenteral but
ot mucosal challenge with the virus (Miller et al., 1989).
urther studies with mucosal administration of a live
ttenuated SIV virus showed that induction of CTL re-
ponses in gut-associated lymphoid tissues was protec-
ive against subsequent infection with the virulent virus
Cranage et al., 1997). However, concerns about safety
as limited testing of the live attenuated vaccines in
umans and increased the need for the development of
ess virulent approaches to induce broad cellular re-
ponses to HIV antigens in mucosal tissues of gut.
1 b
d
To whom reprint requests should be addressed. Fax: (215) 503-
489. E-mail: D_Kozbor@lac.jci.tju.edu.
0042-6822/00 $35.00
Copyright © 2000 by Academic Press
All rights of reproduction in any form reserved.
8To date, induction of HIV-specific CTL responses in
ucosal tissues with nonliving vaccines has been
chieved with the synthetic HIV peptides. In one ap-
roach, a lipidated antigenic peptide containing a part of
he V3 loop from HIV-1IIIB gp160 was encapsulated in PLG
icroparticles and administered by intragastric and na-
al routes (Mora and Tam, 1998). In the second ap-
roach, env-specific peptide was delivered intrarectally
IR) in combination with cholera toxin adjuvant (Belyakov
t al., 1998a,b). Although env-specific CTL responses
nduced by the IR immunization were protective against
ucosal challenge with recombinant vaccinia virus ex-
ressing HIV gp160, cholera toxin causes unacceptable
iarrhea and other complications in humans and in its
resent form can not be used in the final vaccine trials
Levine et al., 1983).
Previous studies have shown that the immunization
fficiency with recombinant proteins or synthetic pep-
ides can be improved by genetic vaccines (Anto´n et al.,
997). Intramuscular or subcutaneous (s.c.) administra-
ion of “naked” plasmid DNA encoding an antigen results
n synthesis of several hundred peptide molecules by the
ells and subsequent development of specific cellular
nd humoral immune responses (Robinson, 1997; Tighe
t al., 1998). However, despite some success of DNA-
ased immunization through i.m. and s.c. routes, oral
elivery of naked DNA has been mostly ineffective
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9IMMUNE RESPONSES INDUCED BY DNA VACCINE TO HIV gp160(Etchart et al., 1997). Oral vaccination is useful not only
ecause it generates mucosal immunity but also be-
ause of its high patient compliance, ease of adminis-
ration, and applicability for mass vaccination. The effi-
acy of orally delivered DNA vaccines has been im-
roved by encapsulating plasmid DNA in PLG
icroparticles for protection from gastric environment
Jones et al., 1997). In the initial study, oral immunization
with PLG microparticles containing plasmid DNA-en-
coded luciferase was shown to stimulate luciferase-spe-
cific serum antibody and mucosal IgA responses (Jones
et al., 1997). Similar experiments carried out with DNA
encoding a known CTL epitope of vesicular stomatitis
virus (VSV) demonstrated induction of VSV peptide-spe-
cific CTL responses (Hedley et al., 1998). Additional stud-
ies by Chen et al. (1998) showed that oral immunization
with PLG-encapsulated plasmid DNA encoding rotavirus
capsid protein induced protection against challenge with
homologous rotavirus and established a precedent for
protective immunity induced by oral DNA vaccines.
In the present study, we have further explored the
possibility of using PLG microparticles as vehicles for an
oral delivery of plasmid DNA encoding HIV env glyco-
protein. We showed that oral, but not i.m., immunization
with PLG microspheres containing plasmid DNA-en-
coded HIV gp160 induced mucosal env-specific cellular
and humoral responses that were protective against re-
combinant HIV env vaccinia virus challenge.
RESULTS
Expression of env-specific mRNA in the
gastrointestinal tract of BALB/c mice
after oral and systemic immunizations
To generate delivery vehicles suitable for oral admin-
istration of DNA vaccines, the pcDNA3.1 plasmid encod-
ing HIV env glycoprotein was encapsulated in PLG mi-
croparticles and used for induction of env-specific cellu-
lar responses in BALB/c mice. The size profile analysis
revealed that .90% of PLG microparticles used for the
delivery of DNA-encoded gp160 were between 1.1 mm
nd 10 mm, with the median diameter size of 6.7 mm. The
microparticles were delivered orally or by i.m. injections
on Days 0, 7, and 14. The expression of env-specific
mRNA in mucosal tissues of small and large intestine
was analyzed 1 week after the third immunization. Total
cellular RNA isolated from the gastrointestinal tract of
immunized and control mice was reverse transcribed
and amplified with env-specific primers. In parallel, am-
plification with primers specific for the murine b-actin
ene was included in the assay as a quality control for
NA extraction and amplification.
Consistent with the previous results, which demon-
trated that microparticles ,10 mm can penetratehrough and between cells of intestinal epithelium (Ma-
hiowitz et al., 1997), an amplified fragment of 322 bporresponding to the env glycoprotein was detected in
he gastrointestinal tract of mice fed with the encapsu-
ated plasmid DNA (Fig. 1, top). Additionally, the pres-
nce of gp160 transcripts in small and large intestine
ndicated that the microparticles displayed strong adhe-
ive interactions with gastrointestinal mucus and main-
ained contact with intestinal epithelium for an extended
eriod of time. In contrast, mice injected i.m. with the
ncapsulated plasmid DNA-encoded gp160 had no de-
ectable env message in the cellular lining of the gastro-
ntestinal tract. The PCR product of 540 bp correspond-
ng to b-actin-specific transcripts was detected in intes-
tinal specimens derived from both groups of immunized
mice as well as control animals immunized orally with
the encapsulated pcDNA3.1 vector (Fig. 1, bottom).
Systemic env-specific IFN-g and antibody responses
induced by DNA vaccination
Studies were initiated to explore the use of orally
delivered PLG-encapsulated plasmid DNA as a strategy
for eliciting systemic and mucosal immune responses.
Because DNA vaccines have most frequently been de-
livered either by i.m. injection of naked DNA plasmid or
by particle bombardment of skin tissue (Wolff et al.,1990;
Yang et al., 1990), we first compared levels of env-spe-
cific immune responses in mice immunized i.m. and
orally with naked or PLG-encapsulated plasmid DNA
encoding gp160. Analysis of IFN-g production in cell-free
supernatants derived from cultures of recombinant
gp160 (rgp160)-stimulated splenocytes revealed compa-
rable IFN-g responses after oral and i.m. immunization
ith 10 mg of env-encoded plasmid DNA encapsulated in
PLG microparticles (Fig. 2A). Similar amounts of IFN-g
were measured in rgp160-stimulated splenocytes de-
FIG. 1. Expression of env-specific transcripts in gastrointestinal tract
of BALB/c mice immunized with plasmid DNA encapsulated in PLG
microparticles. Mice were immunized orally or by i.m. injection with
encapsulated plasmid DNA encoding the env glycoprotein. Control
mice received PLG-encapsulated pcDNA3.1 plasmid. One week after
the third immunization, expression of the env-specific mRNA in muco-
sal tissues of small (S) and large (L) intestine were analyzed by RT–PCR
using env-specific primers (top). Amplification with b-actin-specific
primers was included as a quality control for cellular RNA (bottom). The
PCR products were subjected to electrophoresis on 2% agarose gel.rived from mice immunized i.m. with 100 mg of naked
DNA encoding gp160, whereas i.m. injection of 10 mg of
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10 KANEKO ET AL.this plasmid elicited consistently lower levels of env-
specific IFN-g responses in vitro.
In parallel experiments, we examined induction of env-
specific antibodies in sera of the immunized mice (Fig.
2B). Detectable env-specific antibody responses, with a
titer of 1100 6 230, were measured after i.m. injection of
10 mg of naked DNA encoding gp160, and the antibody
iter increased to 2600 6 650 in mice immunized i.m. with
00 mg of this plasmid. Similar levels of env-specific
serum antibody responses were induced by oral and i.m.
administration of PLG microparticles containing env-en-
coded plasmid DNA (titers 2500 6 866 and 1650 6 500,
respectively). Results of these experiments demon-
strated that the env glycoprotein was expressed in vivo
after immunization with naked as well as PLG-encapsu-
lated plasmid DNA-encoded gp160 and suggested that
PLG encapsulation might be a viable means for the
induction of env-specific immune responses.
Induction of env-specific mucosal IFN-g responses by
NA vaccination
The ability of PLG microspheres containing the gp160-
FIG. 2. Induction of HIV env-specific IFN-g and serum antibody
responses after i.m. and oral administration of naked or PLG-encap-
sulated plasmid DNA encoding gp160. (A) Splenocytes were stimulated
for 3 days with 3 mg/ml of rgp160, and levels of IFN-g in cell-free culture
upernatants were determined by the ELISA assay. Background values
rom unstimulated cultures detected for IFN-g (range, 10–80 pg/ml)
were subtracted from all values given. (B) Sera prepared from murine
blood samples were serially diluted and analyzed for gp160-specific
antibody responses by ELISA on plates coated with rgp160. For gp160-
specific ELISA, sample dilutions were considered positive if the optical
density recorded for that dilution was at least twofold higher than the
optical density recorded for a naive sample at the same dilution.
Results are presented as mean values 6 SD of four mice per group.ncoded plasmid DNA to facilitate cellular uptake by the
ntestinal epithelium led us to analyze whether this type
w
pf delivery system induces env-specific cell-mediated
mmunity in mucosal tissues of gut. The effect of oral and
ystemic immunizations on induction of env-specific
FN-g responses was examined in rgp160-stimulated
cultures established from lymphocytes isolated from
Peyer’s patches and lamina propria. As shown in Fig. 3A,
induction of IFN-g responses to the env glycoprotein was
etected only in gut-associated lymphoid tissues derived
rom mice immunized orally with PLG-encapsulated plas-
id DNA encoding gp160. The levels of env-specific
FN-g production by lymphocytes isolated from lamina
ropria and Peyer’s patches of these mice were 1228 6
84 and 1248 6 559 pg/ml, respectively. In contrast, the
roduction of IFN-g in rgp160-stimulated cultures estab-
ished from lamina propria and Peyer’s patches of mice
mmunized i.m. with naked or PLG-encapsulated plasmid
NA-encoded gp160 was at a background level (Fig. 3A).
nv-specific fecal IgA responses
In subsequent studies, we analyzed induction of intes-
inal env-specific IgA responses by immunization with
aked and PLG-encapsulated plasmid DNA-encoded
p160. As shown in Fig. 3B, mucosal IgA responses
irected to the env glycoprotein were present only in
ecal washes of mice immunized orally, and were not
etected in stools of mice injected i.m. with the env-
ncoded plasmid DNA.
FIG. 3. Analysis of HIV env-specific mucosal IFN-g and IgA re-
ponses after i.m. and oral administration of naked or PLG-encapsu-
ated plasmid DNA encoding gp160. (A) Cells isolated from Peyer’s
atches (hatched bars) and lamina propria (solid bars) were stimulated
or 3 days with 3 mg/ml of rgp160, and levels of IFN-g in cell-free culture
upernatants were determined by the ELISA assay. Background values
rom unstimulated cultures detected for IFN-g were subtracted from all
alues given. (B) The levels of env-specific IgA in fecal wash samples
ere determined by ELISA on plates coated with rgp160. Results are
resented as the mean values 6 SD of four mice per group.
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11IMMUNE RESPONSES INDUCED BY DNA VACCINE TO HIV gp160Env-specific CTL responses
Previous studies by Mora and Tam (1998) demon-
strated that intragastric administration of V3-loop-spe-
cific lipopeptide encapsulated in PLG microparticles
could prime virus-specific CTLs. To determine whether
the effect achieved with encapsulated lipopeptide can be
reproduced with plasmid DNA entrapped in PLG micro-
particles, we analyzed the level of env-specific CTL re-
sponses in spleen, lamina propria, and Peyer’s patches
after oral and i.m. immunizations. Lymphocytes derived
from immunized and control mice were stimulated with
the env-specific, H-2d-restricted peptide I10 (Takahashi
t al., 1996) for 6 days prior to the killing assay. The CTL
ctivities in I10-stimulated cultures were analyzed
gainst 17Cu cells (a clone derived from the H-2d-posi-
ive 3T3 fibroblasts) infected with the recombinant vac-
inia virus expressing the HIV-1IIIB env gene products
vPE16). In parallel, each culture was analyzed for CTL
esponses against 17Cu cells infected with the nonre-
ombinant vaccinia virus (vac) as a negative control.
Consisted with the profile of rgp160-induced IFN-g
responses, env-specific CTL activities were detected in
I10 peptide-stimulated splenocytes derived from mice
immunized orally or i.m. with the DNA vaccine (Fig. 4).
The env-specific CTL responses in these cultures varied
between 27 and 34% specific lysis at the E:T ratio of 50:1.
Cytotoxic activities against vPE16-infected cells were
also detected in I10-stimulated lymphocytes isolated
from Peyer’s patches and lamina propria after oral im-
munization (Fig. 4). The mucosal CTL responses induced
by orally delivered DNA vaccine were approximately two-
fold higher than those measured in cultures established
from lamina propria and Peyer’s patches after i.m. immu-
nization. In mice immunized i.m., the env-specific CTL
activities in Peyer’s patches and lamina priopria did not
differ from responses directed against vac-infected tar-
get cells, and did not exceed the level of lysis measured
in I10 peptide-stimulated cultures derived from control
animals.
Protection against intrarectal challenge with
recombinant vaccinia virus expressing
HIV env glycoprotein
The significance of the env-specific immune re-
sponses in gut-associated lymphoid tissues induced by
orally delivered DNA vaccine was examined in protective
studies against virus challenge via a mucosal route.
BALB/c mice were immunized orally or i.m. with PLG
microparticles containing plasmid DNA-encoded gp160,
and challenged on Day 28 by IR infusion with 2.5 3 107
plaque forming units (PFU) of vPE16. In a control group of
mice, PLG-encapsulated pcDNA3.1 plasmid was deliv-
ered orally prior to the vaccinia virus challenge. To de-
termine whether any protection induced by immunization
with the DNA vaccine was specific for the env glycopro-tein, additional mice were immunized orally with the
env-encoded plasmid DNA prior to the challenge with
vac or the recombinant vaccinia virus expressing the
HIVIIIB gag-pol genes in addition to b-galactosidase
vVK1; Karacostas et al., 1989). Because the vaccinia
irus replicates most efficiently in ovaries (Alexander-
iller et al., 1996), ovaries were removed 5 days after the
hallenge and tested for the vaccinia titer on a mono-
ayer of HuTK2 143B cell line.
As shown in Fig. 5, the control group of mice was
unprotected against the virus challenge. In mice injected
i.m. with PLG-encapsulated plasmid DNA-encoded
gp160, the vaccinia virus titers after the mucosal chal-
lenge with vPE16, vac, or vVK1 were not significantly
different. In mice immunized orally with the env-encoded
plasmid DNA encapsulated in PLG microparticles, the
FIG. 4. Analysis of env-specific CTL responses in spleen (SP), Pey-
er’s patches (PP), and lamina propria (LP) after immunization with
microparticles containing DNA encoding HIV env glycoprotein. Control
mice received orally the PLG-encapsulated pcDNA3.1 plasmid. Lym-
phocytes derived from spleen and the mucosal tissues of gut were
stimulated with the I10 peptides for 6 days in the presence of murine
recombinant IL-2. The env-specific CTL responses were analyzed by
51Cr-release assay in bulk cultures against vPE16-infected 17Cu cells
close symbols) using vac-infected cells as a negative control (open
ymbols). All CTL experiments were run in triplicate with SD ,10%.vPE16 titer in ovaries was 100-fold lower compared to
that of vac or the vVK1 virus expressing unrelated anti-
challen
o the m
12 KANEKO ET AL.gens (Fig. 5). Results of these experiments indicated that
the reduction in the viral titer after orally delivered DNA
vaccine was specific for virus expressing HIV gp160 and
could not be mediated by any nonspecific inflammatory
response induced by immunization with PLG-encapsu-
lated plasmid DNA. Thus it appears that the twofold
difference in the levels of env-specific mucosal immunity
between mice immunized orally and i.m. with the DNA
vaccine could be responsible for the higher resistance to
mucosal viral transmission after oral than after i.m. im-
munization with PLG-encapsulated plasmid DNA encod-
ing gp160.
DISCUSSION
In this study, we demonstrated that orally delivered
plasmid DNA encapsulated in PLG microparticles in-
duced env-specific immune responses that elicited a
significant level of protection against mucosal challenge
with the vPE16 recombinant vaccinia virus. Our results
are consistent with the previous observation that protec-
tive immunity against IR challenge with vPE16 can be
induced in mice immunized IR with env-specific peptide
and cholera toxin (Belyakov et al., 1998a,b). Because the
vaccinia virus does not incorporate gp160 in the virion
but expresses it only in infected cells, these authors
concluded that the protection was mediated by env-
specific CTLs rather than neutralizing antibodies to
gp160 (Belyakov et al., 1998a,b). Consequently although
we cannot exclude the possibility that some antibody-
mediated mechanisms including lysis of infected cells by
FIG. 5. Resistance of mice against mucosal viral challenge. Immuniz
recombinant vaccinia virus expressing gp160IIIB (vPE16; gray bars), non
virus expressing gag-pol antigens (vVK1; black bars). The viral titers in
differences (F 5 14.51; P 5 0.002) in vaccinia virus titers between mice
rally with the env-specific DNA vaccine. The values are presented ascomplement or antibody-dependent cellular cytotoxicity
might have contributed to protection against the vacciniachallenge, these results suggest that the protection was
largely associated with induction of env-specific muco-
sal CTL responses.
Because mucosal immunity constitutes an impressive
first-line defense system that in humans protects some
400 m2 of surface area in adulthood (Miller et al., 1992),
our results suggest that oral DNA vaccination might
represent the most effective approach in providing pro-
tection against HIV infection acquired via mucosal sur-
faces. Oral vaccines will also eliminate the stress asso-
ciated with vaccination via the parenteral route, reduce
costs, and be logistically simple compared with conven-
tional administration routes. These advantages would
not only be of benefit in less developed countries but
also could increase acceptability of and access to vac-
cinations in industrialized nations. Furthermore the PLG
microparticles used in this study are known for their
biocompatibility, biodegradability, composition of non-
toxic, pharmaceutically approved components, adequate
rates of absorption, and a history of safe use in humans
(Eldridge et al., 1991; Morris et al., 1994).
The ability to induce cellular and humoral responses
with recombinant vectors is important because the use
of DNA plasmids to administer HIV immunogens has
additional potential advantages over candidate live-at-
tenuated SIV or HIV vaccines. These includes the fact
that replication of the vector does not depend on the
structural or functional integrity of the expressed HIV
gene product. As results, viral gene products can be
manipulated in ways to create more effective immuno-
control mice were challenged intrarectally with 2.5 3 107 PFU of the
binant vaccinia virus (vac; hatched bars), or the recombinant vaccinia
s were analyzed 5 days after the challenge. Significant group-related
ged with vPE16 and vac or vVK1 were measured in animals immunized
ean numbers 6 SD of PFU per ovaries of five mice per group.ed and
recom
ovariegens than the naturally synthesized products. Promising
potential modifications might act to accelerate antigen
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13IMMUNE RESPONSES INDUCED BY DNA VACCINE TO HIV gp160processing and presentation or alter viral protein struc-
ture to enhance or develop immune responses to viral
targets that are normally masked in the context of intact
viral proteins [i.e., altering the conformation of the env
glycoprotein to increase the responses against function-
ally essential and conserved domains (Kmieciak et al.,
1998b; Reitter and Desrosiers, 1998)].
Previous studies have shown that sustained release of
antigen from microparticles enhances immune re-
sponses in vivo (Hedley et al., 1998). For example, s.c.
administration of microencapsulated staphylococcal en-
terotoxin B strongly potentiated serum IgG responses in
comparison to soluble antigen (Eldridge et al., 1991).
Similarly, mice immunized one time s.c. or intraperitone-
ally with microparticles containing 2–5 mg of the plasmid
DNA-encoded a VSV CTL epitope generated CTL re-
sponses that were greater than those seen in mice
immunized twice i.m. with 200 mg of naked DNA (Hedley
t al., 1998). In our study, the levels of env-specific CTL
ctivities in mice immunized three times with 10 mg of
the encapsulated plasmid DNA were approximately two-
fold higher than those induced with 10 mg of naked DNA
(data not shown). However, cellular responses induced
by a single immunization were very low and did not
provide protection against the recombinant HIV vaccinia
challenge (data not shown). Thus further studies will be
necessary to determine the effect of multiple doses and
kinetics of DNA delivery for an optimal vaccination pro-
tocol. It is also noteworthy that although generation of
cellular immunity after intranasal delivery was not ana-
lyzed in this set of experiments, previous studies with an
env-specific peptide encapsulated in PLG microparticles
showed that the nasal route of immunization was less
effective in inducing CTL responses as compared with
the intragastric administration (Mora and Tam, 1998).
In summary, this study describes the potential of oral
DNA vaccination for induction of mucosal and systemic
HIV env-specific cellular and humoral responses. Al-
though an ultimate HIV vaccine may require incorpora-
tion of other HIV antigens together with costimulatory
molecules or immunomodulatory cytokines that amplify
antigen presentation, these results may facilitate the
development of a new type of protective HIV vaccine in
humans.
MATERIALS AND METHODS
Construction of a recombinant plasmid encoding HIV
env glycoprotein
The env gene from the pIIIB isolate provided by Dr. B.
Cullen (Howard Hughes Medical Institute, Duke Univer-
sity Medical Center, Durham, NC) was used for construc-
tion of the vpu-deleted gp160 segment using a two-step
PCR protocol (Earl et al., 1994). In the first step, two
fragments with the overlapping ends were synthesized
with a set of overlapping primers. One fragment was
a
rgenerated with primer A containing the SalI site and
Kozak sequence annealed to the rev start codon (59-
AAGGTCGACGCCGCCACCATGGCAGGAAGAAGCGGA-
39), in conjunction with primer B (59-GTTATCACTACATTA-
CATGTATTACTTACTG-39), containing the translation ter-
mination codons before the vpu start codon. The other
fragment was generated with primer C (59-GTAATGTAGT-
GATAACAAATAGCAATAGTAGCATTAG-39) in conjunction
with and primer D (59-ACAGGTACCCCATAATAGTAGACT-
GTG-39), containing the KpnI restriction site. These two
fragments were then used together in a second reaction
along with primers A and D to generate the vpu-deleted
nv fragment. The final product was digested with SalI
nd KpnI and exchanged with the analogous fragment
erived from the pSVIII-env plasmid provided by Dr. J.
odroski (Dana-Farber Cancer Institute, Boston, MA).
he entire fragment between SalI and XhoI restriction
ites was cloned into the XhoI restriction site of the
cDNA3.1(2) expression vector containing the CMV pro-
oter (Invitrogen, Carlsbad, CA). After sequencing, the
xpression of the env gene products was confirmed by
mmunoprecipitation of the env glycoprotein from radio-
abeled 3T3 cells transfected with the env-encoded
cDNA3.1 plasmid.
ncapsulation of plasmid DNA in PLG microparticles
Controlled-release microparticles with entrapped
lasmid DNA were prepared with a poly(DL-lactide-co-
glycolide) polymer (Sigma, St. Louis, MO) using the wa-
ter-in-oil-in-water solvent evaporation method (Hedley et
al., 1998). Briefly, the polymers had a 50:50 ratio of lac-
tide:glycolide and an inherent viscosity of 0.47 DL/g. 200
g of PLG dissolved in 6 ml of dichloromethane (Sigma)
as mixed by vortexing with 0.3 ml of TE buffer (pH 7.4)
ontaining 5 mg of plasmid DNA and sonicated for 1 min
Branson Sonifier 450, Danbury, CT). The resulting solu-
ion was emulsified in 8% polyvinyl alcohol solution (PVA)
Sigma) using the PowerGen 125 homogenizer (Fisher
cientific, Pittsburgh, PA). The emulsion was then poured
nto 100 ml of 8% PVA and stirred magnetically overnight
t room temperature to allow solvent evaporation and
icroparticle formation. The microparticles were iso-
ated by centrifugation, washed three times in water, and
reeze dried. The final product was stored in a desiccator
elow 220°C. The microsphere size profile was ana-
yzed on a Coulter Counter (Miami, FL). DNA integrity
as determined by dissolving 25 mg of the PLG micro-
articles in 500 ml of chloroform. After adding 500 ml of
water, DNA was extracted by ethanol precipitation and
analyzed on an agarose gel. To measure incorporation of
DNA, the PLG microparticles were dissolved in 0.1 M
NaOH at 100°C for 10 min, and DNA content was deter-
mined by the A260 measurement as described (Chen etl., 1998). Incorporation of DNA into microparticles
anged from 1.3 to 2.1 mg of DNA per mg of PLG.
l
a
t
I
i
J
t
m
a
b
g
P
s
m
s
t
e
s
t
e
w
(
s
e
A
s
(
1
s
c
f
p
w
s
m
p
4
E
d
c
w
s
d
(
d
i
c
c
l
4
4
w
p
y
w
p
s
I
i
A
T
t
14 KANEKO ET AL.To analyze whether plasmid DNA encapsulated in the
PLG microparticles could be delivered and expressed in
vitro, murine peritoneal macrophages were plated in a
24-well plate at a concentration of 105 cells/ml. After 3
days of culture, 1 mg of microparticles containing plas-
mid DNA encoding the env glycoprotein was resus-
pended in 500 ml of PBS, and 5 ml of the mixture was
added to each well. The plates were incubated at 37°C
for 4 h, after which media and microspheres were re-
moved and fresh media were added. Control cultures
included cells that received microparticles with the
pcDNA3.1 plasmid only. Five days later, cells were fixed
with 3.7% paraformaldehyde and immunostained with a
mixture of sera derived from HIV-infected individuals
followed by incubation with peroxidase-conjugated
(Fab9)2 portion of goat anti-mouse Ig (Sigma). Intracellu-
ar expression of the env glycoprotein was examined
fter incubation with 0.7 mg/ml of 3,39diaminobenzidine
etrahydrochloride (Sigma).
mmunization and expression of the env glycoprotein
n vivo
Female BALB/c (H-2d) mice were purchased from the
ackson Laboratory (Bar Harbor, ME) and were main-
ained in a specific pathogen-free microisolator environ-
ent. Mice were immunized three times (on Days 0, 7,
nd 14) with naked or PLG-encapsulated plasmid DNA
y i.m. injection into quadriceps or orally using a 24-
auge feeding needle (Popper and Sons, Inc., New Hyde
ark, NY). Control mice received orally the PLG-encap-
ulated pcDNA3.1 plasmid. One week after the last im-
unization, expression of the env-specific mRNA in
mall and large intestines were analyzed by reverse
ranscriptase-polymerase chain reaction (RT–PCR) using
nv-specific primers. Briefly, 1 cm of tissue from the
mall intestine was excised 5 cm apart from the gas-
roduodenal site, and 1 cm of the large intestine was
xcited 2 cm apart from the appendix site. Cellular RNA
as isolated from frozen intestinal tissue with TRIZOL
Life Technologies, Grand Island, NY) and reverse tran-
cribed, and cDNA was amplified with env-specific prim-
rs (59-AACGGATCCTTAGCACTTATCTGG-39) and (59-
CGTCGACCTCGAGTTATAGCAAAATCCTTTC-39) corre-
ponding to gp160 from nucleotides 2248 to 2570
Kmieciak et al., 1998a). Amplification of cDNA with b-ac-
tin-specific primers (Clontech Laboratories, Inc., Palo
Alto, CA) was used as a quality control. PCR products
were separated by agarose gel electrophoresis. Ampli-
fication without RT mixture, or with distilled water instead
of cDNA in the PCR reaction mixture, served as a control
for possible contamination.
Cell purificationInduction of env-specific Th1 and CTL responses in
Peyer’s patches, lamina propria, and spleen were ana-
0
flyzed 3 weeks after the third immunization. Lymphocytes
from lamina propria were dissociated into single cells by
enzymatic digestion as described (Belyakov et al.,
998b). Briefly, the large and small intestines were dis-
ected from individual mice and the mesenteric and
onnective tissues carefully removed. Fecal material was
lushed from the lumen with medium. After the Peyer’s
atches were identified and removed from the intestinal
all, the intestines were opened longitudinally, cut into
hort segments, and washed extensively in complete
edium. To remove the epithelial cell layer, tissues were
laced into 20 ml of 1 mM EDTA and incubated twice (for
0 min and then for 20 min) at 37°C with stirring. After the
DTA treatment, tissues were washed in complete me-
ium for 10 min, placed into 50 ml of RPMI 1640 medium
ontaining 10% FCS and incubated for 15 min at 37°C
ith stirring. To isolate lamina propria lymphocytes, tis-
ues were cut into small pieces and incubated in me-
ium containing collagenase type VIII, 300 units/ml
Sigma) for 50 min at 37°C with stirring. This collagenase
issociation procedure was repeated two times and the
solated cells pooled and washed again. To remove dead
ells and tissue debris, cells were passed through a
otton-glass wool column (Fisher Scientific) and then
ayered onto a discontinuous gradient containing 75 and
0% Percoll (Sigma). After 20 min centrifugation (600 g) at
°C, the interface layer between the 75 and 40% Percoll
as carefully removed and washed with medium. This
rocedure provided .95% viable lymphocytes with a cell
ield of 1.5–2 3 106 lymphocytes per mouse. Spleen cells
ere aseptically removed and single cell suspension
repared by gently teasing the cells through sterile
creens.
n vitro stimulation assay
Lymphocytes from spleen (3 3 106 cells/ml), Peyer’s
patches and lamina propria (2 3 106 cells/ml) were
ncubated in 96-well plate (Linbro, ICN Biomedicals, Inc.,
urora, OH) with 3 mg/ml of rgp160 (Immunodiagnostics
Inc., Bedford, MA) or medium only. On the third day of
stimulation, culture supernatants were collected and an-
alyzed for IFN-g production by the ELISA assay (Quan-
tikine, R&D Systems, Minneapolis, MN) according to the
manufacturer’s protocol.
Anti-gp160 antibody ELISA
A direct ELISA assay was used to determine the pres-
ence of env-specific antibodies in serum and fecal
washes. Ninety-six-well Maxisorp ELISA plates (Nunc,
Naperville, IL) were coated overnight at 4°C with 100 ml
of 3 mg/ml rgp160 as described (Barouch et al., 1998).
he rest of the ELISA assay was conducted at room
emperature. Following a wash with PBS containing
.05% Tween 20 (PBS/Tween 20), the wells were blocked
or 2 h with a solution containing 2% BSA (Sigma) and
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blood samples, serially diluted in PBS/Tween 20, and
added to ELISA wells. After incubation at room temper-
ature for 1 h, the plate was washed three times and then
incubated with a 1/10,000 dilution of a peroxidase-con-
jugated goat anti-mouse Ig (IgG, IgM, and IgA; Sigma) in
PBS/Tween. The plates were washed three times and
developed with O-phenylenediamine (0.4 mg/ml; Sigma)
in 0.05 M phosphate-citrate buffer containing 0.03% so-
dium perborate (Sigma), stopped with 0.4 N sulfuric acid,
and analyzed at 450 nm with an ELISA plate reader
(Dynatech MRX, Chantilly, VA). Sample dilutions were
considered positive if the optical density recorded for
that dilution was at least twofold higher than the optical
density recorded for a naive sample at the same dilution
(Staats et al., 1996).
The presence of env-specific IgA in fecal samples was
measured by ELISA using 1/1000 dilution of peroxidase
conjugated-goat anti-mouse IgA (Sigma). Fecal washes
were prepared from fecal samples as described (Staats
et al., 1996). Briefly, fresh fecal samples (100 mg) were
mixed with 1 ml of PBS, incubated at room temperature
for 15 min, vortexed, and centrifuged in a microcentrifuge
for 10 min. Supernatants were collected and stored at
220°C until assayed for anti-gp160 antibodies.
Vaccinia viruses
The recombinant vaccinia viruses expressing the full-
length HIV-1IIIB gp160 (vPE16; Earl et al., 1991), the HIV-
1IIIB gag-pol genes (vVK1; Karacostas et al., 1989), and the
R strain of nonrecombinant vaccinia virus (vac; Mac-
ett et al., 1982) were provided by Dr. B. Moss (Labora-
ories of Viral Diseases, National Institute of Allergy and
nfectious Diseases, Bethesda, MD). Both vPE16 and
VK1 express b-galactosidase.
CTL assay
Lymphocytes from spleen, Peyer’s patches, and lam-
ina propria were cultured at 2 3 106 cells/ml in 24-well
ulture plates with medium containing 1 mM of the env
peptide I10 (RGPGRAFVTI, amino acids 318–327) (Taka-
hashi et al., 1996) and 10% T cell stimulatory factor
(T-STIM Culture Supplement, Collaborative Biomedical
Products, Bedford, MA) as a source of exogenous IL-2.
After 3 days of stimulation, cells were split and cultured
in medium supplemented with 0.3 ng/ml of recombinant
mouse IL-2 (Pharmingen, San Diego, CA). Cytolytic ac-
tivity of CTL lines was analyzed after 6 days of cultures
by a standard 4 h 51Cr release assay against 17Cu cells
provided by Dr. M. Wysocka, The Wistar Institute, Phil-
delphia, PA) infected with vPE16 or vac. The percent
pecific lysis was calculated as: ([cpm experimental re-
ease 2 cpm spontaneous release]/[cpm maximum re-
lease 2 cpm spontaneous release]) 3 100. Maximum
release was determined from supernatants of cells thatwere lyzed by addition of 5% Triton X-100. Spontaneous
release was determined from target cells incubated with
medium only.
Protection against intrarectal challenge
with vaccinia viruses
On Day 28, mice were challenged IR with 2.5 3 107
PFU of vPE16, vac, or vVK1. Five days after the challenge,
the mice were killed, ovaries were removed, homoge-
nized, sonicated, and assayed for vaccinia virus titers by
plating serial 10-fold dilutions on a plate of human HuTK2
143B indicator cells, staining with crystal violet and
counting plaques at each dilution.
Statistical analysis
Mixed model analysis of variance (Winer, 1971) was
used to compare mean values of the vaccinia virus titers
between mice challenged with vPE16, vac, or vVK1 after
oral and i.m. immunization with PLG-encapsulated plas-
mid DNA encoding gp160, and after orally delivered
PLG-encapsulated pcDNA3.1 plasmid.
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